BioSpace News Archive

- Focused on omidubicel, an advanced cell therapy, including a review of Phase 3 clinical data, and GDA-201, a natural killer cell therapy – - Event to feature an omidubicel patient’s perspective - - Live webcast on December 9, 2020 at 8:00 a.m. ET -

Oramed Pharmaceuticals Inc. (Nasdaq: ORMP) (TASE: ORMP) (www.oramed.com), a clinical-stage pharmaceutical company focused on the development of oral drug delivery systems, announced today it has screened the first patients in a global trial of its oral insulin capsule ORMD-0801 for the treatment of Nonalcoholic steatohepatitis (NASH).

Allogene Therapeutics, Inc. (Nasdaq: ALLO), a clinical-stage biotechnology company pioneering the development of allogeneic CAR T (AlloCAR T™) therapies for cancer, today announced that management will review initial results presented at the American Society of Hematology Annual Meeting from the ALLO-715 UNIVERSAL Phase 1 trial in relapsed/refractory multiple myeloma

Syneos Health, Inc. announced the pricing of the previously announced underwritten secondary offering by affiliates of Thomas H. Lee Partners, L.P. and Advent International Corporation of an aggregate of 6,000,000 shares of the Company’s common stock at a price to the public of $61.90 per share.

Spero Therapeutics, Inc. (Nasdaq: SPRO), a multi-asset clinical-stage biopharmaceutical company focused on identifying, developing and commercializing treatments in high unmet need areas involving multi-drug resistant bacterial infections and rare diseases, today announced the appointment of Tamara Joseph, J.D., L.L.M., as Chief Legal Officer, effective as of today.

Seqirus, a global leader in influenza prevention, is presenting key research at the Canadian Immunization Conference 2020 (CIC) contributing to Canadian public health pro

The University of Toronto Department of Medical Imaging’s partnership with International Medical Solutions (“IMS”) has enabled Canada’s most extensive diagnostic radiology training program to continue its comprehensive hands-on training and assessment of students and residents without compromising academic rigor or a competency-based experience.

3D printing leader Stratasys Ltd. (NASDAQ: SSYS) has enhanced its J750 Digital Anatomy™ 3D printer with advanced bone capabilities that don’t just look real but are actually biomechanically realistic, backed by clinical research. The software upgrade enables the systems to mimic porous bone structures, f

Bacainn Therapeutics, Inc., a Company developing novel therapies to address uncontrolled inflammation, today announced the successful completion of the company’s Phase 1, first-in-human clinical trial of BT051, a novel, orally administered, gut-selective inhibitor of migration and activation of neutrophils.

HabitNu, a CDC designated first-of-its-kind umbrella organization for Diabetes Prevention Program (DPP) providers, has achieved full CDC recognition for its online program for the third consecutive year. CDC’s full recognition for DPP is a testament to the provider’s ability to run the program according to rigorous standards implemented b